[go: up one dir, main page]

AR133696A1 - Compuestos de fenil oxooxazolil piperidinadiona sustituida - Google Patents

Compuestos de fenil oxooxazolil piperidinadiona sustituida

Info

Publication number
AR133696A1
AR133696A1 ARP240102317A ARP240102317A AR133696A1 AR 133696 A1 AR133696 A1 AR 133696A1 AR P240102317 A ARP240102317 A AR P240102317A AR P240102317 A ARP240102317 A AR P240102317A AR 133696 A1 AR133696 A1 AR 133696A1
Authority
AR
Argentina
Prior art keywords
compounds
piperidinadione
oxooxazolyl
substituted phenyl
protein
Prior art date
Application number
ARP240102317A
Other languages
English (en)
Inventor
Pravin Sudhakar Shirude
Suresh Babu Vishwa Krishna Penmetsa
Bharat Dinkar Shimpukade
Emily Charlotte Cherney
Durgarao Kantheti
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR133696A1 publication Critical patent/AR133696A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se divulgan compuestos de la fórmula (1) o estereoisómeros, tautómeros o sales de los mismos, en los que R se define en el presente documento. También se divulgan métodos para utilizar dichos compuestos para disminuir los niveles de proteína Ikaros, proteína Helios, proteína Aiolos y proteína Eos; y composiciones farmacéuticas que comprenden dichos compuestos. Estos compuestos son útiles en el tratamiento de infecciones virales y trastornos proliferativos, como por ejemplo el cáncer.
ARP240102317A 2023-09-02 2024-08-30 Compuestos de fenil oxooxazolil piperidinadiona sustituida AR133696A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN202311058935 2023-09-02

Publications (1)

Publication Number Publication Date
AR133696A1 true AR133696A1 (es) 2025-10-22

Family

ID=92931757

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240102317A AR133696A1 (es) 2023-09-02 2024-08-30 Compuestos de fenil oxooxazolil piperidinadiona sustituida

Country Status (6)

Country Link
EP (1) EP4568957A1 (es)
JP (1) JP7789280B1 (es)
KR (1) KR102834908B1 (es)
AR (1) AR133696A1 (es)
TW (1) TW202525802A (es)
WO (1) WO2025049840A1 (es)

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
CA2602777C (en) 2005-03-25 2018-12-11 Tolerrx, Inc. Gitr binding molecules and uses therefor
TWI382974B (zh) 2005-12-20 2013-01-21 英塞特公司 作為吲哚胺２，３-二氧化酶調節劑之ｎ-羥基甲脒基雜環化物
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
BE1017683A3 (fr) 2007-07-12 2009-03-03 Drever Internat Sa Procede, dispositif et systeme de traitement thermique d'une bande metallique en defilement.
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP2011523616A (ja) 2008-05-29 2011-08-18 サン−ゴバン サントル ドゥ ルシェルシェ エ デトゥードゥ ユーロペン チタン酸アルミニウムを含有する多孔質構造体
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP4331604B9 (en) 2008-12-09 2025-07-23 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
CA2772613C (en) 2009-09-03 2020-03-10 Schering Corporation Anti-gitr antibodies
HUE044179T2 (hu) 2009-12-10 2019-10-28 Hoffmann La Roche Elsõsorban humán CSF1R extracelluláris domén 4-et megkötõ antitestek és ezek alkalmazása
SG10201604336VA (en) 2010-03-04 2016-07-28 Macrogenics Inc Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
EP2542588A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
NZ603193A (en) 2010-05-04 2014-07-25 Five Prime Therapeutics Inc Antibodies that bind csf1r
MY177065A (en) 2010-09-09 2020-09-03 Pfizer 4-1bb binding molecules
NO2694640T3 (es) 2011-04-15 2018-03-17
PT2699264T (pt) 2011-04-20 2018-05-23 Medimmune Llc Anticorpos e outras moléculas que ligam b7-h1 e pd-1
ES2808152T3 (es) 2011-11-28 2021-02-25 Merck Patent Gmbh Anticuerpos anti-PD-L1 y usos de los mismos
BR112014012624A2 (pt) 2011-12-15 2018-10-09 F Hoffmann-La Roche Ag anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
CA2861122A1 (en) 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
HK1212214A1 (en) 2012-08-31 2016-06-10 戊瑞治疗有限公司 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
EP3838316B1 (en) 2013-07-11 2024-04-03 Alexza Pharmaceuticals, Inc. Drug delivery and drug cessation system
AU2018220840A1 (en) * 2017-02-14 2019-09-19 Effector Therapeutics, Inc. Piperidine-substituted Mnk inhibitors and methods related thereto
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
BR112022009514A2 (pt) * 2019-11-19 2022-08-16 Bristol Myers Squibb Co Compostos úteis como inibidores de proteína helios
SMT202500281T1 (it) * 2021-04-06 2025-09-12 Bristol Myers Squibb Co Composti ossoisoindolinici sostituiti con piridinile
AU2022306297A1 (en) * 2021-07-09 2024-02-08 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2

Also Published As

Publication number Publication date
TW202525802A (zh) 2025-07-01
JP2026502937A (ja) 2026-01-27
KR20250049563A (ko) 2025-04-11
WO2025049840A1 (en) 2025-03-06
EP4568957A1 (en) 2025-06-18
KR102834908B1 (ko) 2025-07-16
JP7789280B1 (ja) 2025-12-19

Similar Documents

Publication Publication Date Title
CL2020002511A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
CO2019011762A2 (es) Compuestos que inhiben la proteína mcl-1
EA202190006A1 (ru) Пуриноновые соединения и их применение при лечении рака
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
ECSP055640A (es) Composiciones de pirazol útiles como inhibidores de gsk-3
PA8583401A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
UY28279A1 (es) Fenacilo 2 -hidroxi - 3 - diaminoalcanos
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
UY28280A1 (es) 2- hidroxi - 3- diaminoalcanos de benzamida
ECSP21080096A (es) Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra
CL2020001930A1 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas.
CL2021003568A1 (es) Compuestos heteroaromáticos como inhibidores de vanina (divisional de solicitud n° 202101198)
UY27924A1 (es) Compuestos tipo diarilureas fluoradas
CO2022011258A2 (es) Pirazolo-pirimidinas sustituidas y usos de las mismas
CO2024006727A2 (es) Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismos
MX2024011755A (es) Derivados sulfonamidicos como inhibidores de la cinasa dependiente de ciclina 2 (cdk2)
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
CL2023003921A1 (es) Inhibidores de transglutaminasas
CO2025016753A2 (es) Inhibidores de gsk3α y métodos de uso de estos
AR133696A1 (es) Compuestos de fenil oxooxazolil piperidinadiona sustituida
MX2025001128A (es) Compuestos sustituidos de ip5